Long-term results of ultrasound (US)-guided radiofrequency ablation (RFA) of benign thyroid nodules: State of the art and future perspectives–A systematic review - 25/09/21
Resumen |
Radiofrequency-ablation (RFA) is one of the most widely used treatment in specialized thyroid centers but, due to the relatively recent introduction into clinical Practice, there are limited long-term follow-up studies.
Aim |
to review outcomes of RFA on solid nonfunctioning (or autonomous) thyroid nodules (TN) on a long-time period for assessing the results in term of efficacy, complications, and costs and to compare them to the current indications of RFA. A systematic review was performed using EMBASE and Medline library data. Between 2008 and 2021, seventeen studies evaluated RFA for the treatment of benign solid TN, with an at least 18 months of follow-up. Data extraction and quality assessment were performed by two endocrinologists according to PRISMA guidelines. The majority of the studies were retrospective study and reported 933 nodules, mostly solid. Baseline volume ranged between 6.1±9.6 and 36.3±59.8mL. Local analgesia was used and the time duration of the treatment was between 5±2 and 22.1±10.9minutes. The volume reduction rate at 12 months ranged from 67 to 75% for the nodule treated with a single Procedure and reached to 93.6±9.7% for nodules treated with repeat ablations. The regrowth rate at 12 months ranged from 0 to 34%. All the studies consistently validated the long-term clinical efficacy and the substantial safety of RFA for the treatment of benign TNs. TA, however, is an operator-dependent technique and should be performed in centers with specific expertise with a rigorous selection of the nodules.
El texto completo de este artículo está disponible en PDF.Esquema
Vol 82 - N° 5
P. 394 - octobre 2021 Regresar al númeroBienvenido a EM-consulte, la referencia de los profesionales de la salud.